Toplum kökenli pnömonilerde kısa süreli tedavi yaklaşımları

Antibiyotiklerin uzun süre kullanımı, ilaç direnci gelişimi, kolonizasyonda ve tedavi maliyetinde artış gibi bazı dezavantajları beraberinde getirmektedir. Diğer yandan, birçok pnömoni tanı-tedavi rehberinde ileri sürülen tedavi süreleri arasında farklılıklar söz konusudur. Son yıllarda özellikle yeni florokinolonlar ve makrolidlerle yapılan çalışmalarda, pnömoni tedavisinde antibiyotiklerin kısa süreli kullanımının uzun süreli tedaviler kadar etkin olduğu ve dirençli suşlarla kolonizasyon ve tedavi maliyetleri konusunda avantaj sağladıkları bildirilmiştir. Bu derlemede, güncel literatür ışığında, toplum kökenli pnömonilerde kısa süreli tedaviler gözden geçirilmiştir.

Short course antibiotherapies in community acquired pneumonia

The use of antibiotics for longer duration contributes to some disadvantageous conditions such as the development of resistant bacteria, increased bacterial colonization and an increase in the costs. In addition, in terms of suggested therapy durations, there are some differences between guidelines for the diagnosis and treatment of pneumonia. In some studies, especially in the studies performed using new flouroquinolon and macrolide antibiotics in recent years, it has been shown that short course antimicrobial therapies for pneumonia are as effective as the traditional long therapies and are advantageous for lowering bacterial colonization and costs. In this article, short course therapy in community acquired pneumonia is reviewed under the light of current literature.

PDF

___

1. Jacobs RF. Judicious use of antibiotics for common pediatric respiratory infections. Pediatr Infect Dis J 2000; 19:938-43.
2. McCaig LF, Hughes JM. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA 1995; 273: 214-9.
3. Özlü T, Çetinkaya F, Öztuna F, Bülbül Y. Trabzon merkez sağlık ocaklarına başvuran olgularda solunum yolu infeksiyonlarının değerlendirilmesi. Toraks Dergisi 2002; 3(Ek 1): 41.
4. Alves DW, Kennedy MT. Community-acquired pneumonia in casualty: Etiology, clinical features, diagnosis, and management (or a look at the “new” in pneumonia since 2002). Curr Opin Pulm Med 2004; 10: 166-70.
5. Arseven O, Özlü T, Aydın G ve ark. Toraks Derneği erişkinlerde toplum kökenli pnömoni tanı ve tedavi rehberi. Toraks Dergisi 2002; 3 (Ek 3): 1-15.
6. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community- acquired pneumonia in adults. Clin Infect Dis 2007;44 (Suppl 2): 27-72.
7. Alfageme I, Aspa J, Bello S, et al. Guidelines for the diagnosis and management of community-acquired pneumonia. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Arch Bronconeumol 2005; 41: 272-89.
8. ALAT work group. Update to the Latin American Thoracic Association (ALAT) recommendations on community acquired pneumonia. Arch Bronconeumol 2004;40: 364-74.
9. British Thoracic Society. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56 (Suppl 4): 1-64.
10. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: Implications for practice guidelines. JAMA 1998; 279: 1452-7.
11. Li JZ, Winston LG, Moore DH, Bent S. Efficacy of shortcourse antibiotic regimens for community-acquired pneumonia: A meta-analysis. Am J Med 2007; 120: 783-90.
12. Guay D. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63: 2169-84.
13. File T. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 (Suppl 3): 159-64.
14. Juven T, Mertsola J, Waris M, et al. Clinical response to antibiotic therapy for community-acquired pneumonia. Eur J Pediatr 2004; 163: 140-4.
15. Metlay JP, Atlas SJ, Borowsky LH, Singer DE. Time course of symptom resolution in patients with communityacquired pneumonia. Respir Med 1998; 92: 1137-42.
16. Stralin K, Sjoberg L, Holmberg H. Short-course beta-lactam treatment for community-acquired pneumonia. Clin Infect Dis 2004; 38: 766-7.
17. Yalnız E, Yılmaz U, Utkaner G ve ark. Toplumsal kökenli pnömoni ve KOAH’ın akut infeksiyöz alevlenmesinin hastanede klaritromisin ile ardışık tedavisi. Tuberk Toraks 2000: 48: 115-20.
18. Schönwald S, Skerk V, Petricevic I, et al. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10: 877-80.
19. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38-44.
20. Capelastegui A, Espana PP, Quintana JM, et al. Management of community-acquired pneumonia and secular trends at different hospitals. Respir Med 2005; 99: 268-78.
21. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. Antimicrob Agents Chemother 2000;44: 1796-802.
22. Ekim N, Köktürk O, Levent E, Çilli A. Toplum kökenli pnömoni olgularında “Ardışık Tedavi”. Tuberk Toraks 1999; 47: 172-8.
23. Karlıkaya C, Hancı E, Öztürk D ve ark. Hastane tedavisi gerektiren pnömonilerde sefepimin etkinliği ve prognostik faktörler. Solunum Hastalıkları Dergisi 1999; 10: 106-14.
24. Ünlü M, Cirit M, Orman A. Afyon ve ilçelerindeki hekimlerin toplum kökenli pnömonilerde tanı ve tedavi yaklaşımları. Akciğer Arşivi 2002; 1: 9-16.
25. Mandell LA, File TM Jr. Short-course treatment of community- acquired pneumonia. Clin Infect Dis 2003; 37:761-3.
26. Özlü T, Bülbül Y, Özsu S. Ulusal verilerle toplum kökemli pnömoniler. Tuberk Toraks 2007; 55: 191-212.
27. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol 1979; 73: 235-40.
28. Perez-Gorricho B, Ripoll M; PACE Study Group. Does short-course antibiotic therapy better meet patient expectations? Int J Antimicrob Agents 2003; 21: 222-8.
29. Harris CM, Lloyd DC. Consider short courses of antibiotics. BMJ 1994; 308: 919.
30. Peltola H, Vuori-Holopainen E, Kallio MJ; SE-TU Study Group. Successful shortening from seven to four days of parenteral beta-lactam treatment for common childhood infections: A prospective and randomized study. Int J Infect Dis 2001; 5: 3-8.
31. Canet JJ, Garau J. Importance of dose and duration of beta-lactam therapy in nasopharyngeal colonization with resistant pneumococci. J Antimicrob Chemother 2002; 50 (Suppl 50): 39-43.
32. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: A randomized trial. JAMA 2001;286: 49-56.
33. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-70.
34. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: A multicentre double-blind trial. Lancet 2002; 360: 835-41.
35. Agarwal G, Awasthi S, Kabra SK, et al; ISCAP Study Group. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: A multicentre randomised controlled trial. BMJ 2004;328: 791.
36. Camargos PA, Guimaraes MD, Ferreira CS. Benzathine penicillin for unilateral lobar or segmental infiltrates presumptively caused by Streptococcus pneumoniae in children 2-12 years old. J Trop Pediatr 1997; 43: 353-60.
37. Siegel RE, Alicea M, Lee A, Blaiklock R. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: A prospective, randomized, double-blind study. Am J Ther 1999; 6: 217-22.
38. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm. Clin Infect Dis 2003;37: 752-60.
39. Dunbar LM, Khashab MM, Kahn JB, et al. Efficacy of 750 mg, 5 day levofloxacin in the treatment of communityacquired pneumonia caused by atypical pathogens. Curr Med Res Opin 2004; 20: 555-63.
40. File TM Jr, Milkovich G, Tennenberg AM, et al. Clinical implications of 750 mg, 5 day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004; 20: 1473-81.
41. Shorr AF, Khashab MM, Xiang JX, et al. Levofloxacin 750 mg for 5 days for the treatment of hospitalized fine risk class III/IV community-acquired pneumonia patients. Respir Med 2006; 100: 2129-36.
42. File TM Jr, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: A randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60: 112-20.
43. Mocan MZ, Mocan H, Sönmez M. Toplumsal kaynaklı pnömonilerde 3 günlük azitromisin tedavisi. ANKEM Kongresi, Bildiri Kitapçığı, Antalya 1997: 152.
44. Kiter G. Azitromisin’in erişkinde ağır olmayan toplum kökenli pnömoni tedavisinde kullanımı: Etkinlik ve güvenilirlik araştırması. Adnan Menderes Üniversitesi Tıp Fakültesi Dergisi 2000; 1: 11-5.
45. O’Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828-33.
46. Roord JJ, Wolf BH, Gossens MM, Kimpen JL. Prospective open randomized study comparing efficacies and safeties of a 3 day course of azithromycin and a 10 day course of erythromycin in children with community-acquired acute lower respiratory tract infections. Antimicrob Agents Chemother 1996; 40: 2765-8.
47. Schönwald S, Gunjaca M, Kolacny-Babic L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother 1990; 25 (Suppl A): 123-6.
48. Schönwald S, Barsic B, Klinar I, Gunjaca M. Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. Scand J Infect Dis 1994;26: 706-10.
49. Schönwald S, Kuzman I, Oreskovic K, et al. Azithromycin: Single 1.5 g dose in the treatment of patients with atypical pneumonia syndrome-a randomized study. Infection 1999; 27: 198-202.
50. Drehobl MA, De Salvo MC, Lewis DE, Breen JD. Singledose azithromycin microspheres vs clarithromycin extended release for the treatment of mild-to-moderate community- acquired pneumonia in adults. Chest 2005; 128:2230-7.
51. Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3 day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997; 9: 141-6.
52. Harris JA, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community-acquired pneumonia in children. Pediatr Infect Dis J 1998;17: 865-71.
53. Kinasewitz G, Wood RG. Azithromycin versus cefaclor in the treatment of acute bacterial pneumonia. Eur J Clin Microbiol Infect Dis 1991; 10: 872-7.
54. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54: 515-23.
55. Gordon EM, Blumer JL. Rationale for single and high dose treatment regimens with azithromycin. Pediatr Infect Dis J 2004; 23 (Suppl 2): 102-7.
56. Arman D. Antibiyotiklerin farmakokinetik ve farmakodinamiği. Leblebicioğlu H, Usluer G, Ulusoy S (editörler). Güncel Bilgiler Işığında Antibiyotikler. Ankara: Bilimsel Tıp Yayınevi, 2003: 75-90.
57. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163: 1371-5.
58. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: Prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-82.
59. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: A randomized trial. JAMA 2003; 290:2588-98.
60. Singh N, Rogers P, Atwood CW, et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription. Am J Respir Crit Care Med 2000; 162: 505-11.